BE2022C501I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2022C501I2 BE2022C501I2 BE2022C501C BE2022C501C BE2022C501I2 BE 2022C501 I2 BE2022C501 I2 BE 2022C501I2 BE 2022C501 C BE2022C501 C BE 2022C501C BE 2022C501 C BE2022C501 C BE 2022C501C BE 2022C501 I2 BE2022C501 I2 BE 2022C501I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003020854 | 2003-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2022C501I2 true BE2022C501I2 (cg-RX-API-DMAC7.html) | 2023-03-07 |
Family
ID=32820637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2022C501C BE2022C501I2 (cg-RX-API-DMAC7.html) | 2003-01-29 | 2022-01-03 |
Country Status (26)
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| JPWO2007011072A1 (ja) * | 2005-07-22 | 2009-02-05 | 武田薬品工業株式会社 | 早発排卵の防止剤 |
| US20100061976A1 (en) * | 2008-07-24 | 2010-03-11 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject |
| WO2010026993A1 (ja) | 2008-09-03 | 2010-03-11 | 武田薬品工業株式会社 | 製剤における吸収性改善方法および吸収性が改善された製剤 |
| EP2385832B1 (en) * | 2009-01-08 | 2015-07-15 | Curis, Inc. | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety |
| US8993634B2 (en) | 2010-06-02 | 2015-03-31 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to Her2/neu receptor complex |
| WO2011153050A1 (en) | 2010-06-02 | 2011-12-08 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to her2/neu receptor complex |
| PT3111938T (pt) | 2011-04-01 | 2019-07-10 | Curis Inc | Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco |
| PL2776038T3 (pl) * | 2011-11-11 | 2018-06-29 | Gilead Apollo, Llc | Inhibitory acc i ich zastosowania |
| LT3415517T (lt) * | 2012-09-28 | 2022-06-10 | Takeda Pharmaceutical Company Limited | Kristalinė 1-(4-(1-(2,6-difluorbenzil)-5-dimetilaminometil-3-(6-metoksipiridazin-3-il)-2,4-diokso-1,2,3,4- tetrahidrotieno(2,3-d)pirimidin-6-il)fenil)-3-metoksikarbamido forma |
| US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
| EP2881391A1 (en) | 2013-12-05 | 2015-06-10 | Bayer Pharma Aktiengesellschaft | Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof |
| RS64377B1 (sr) * | 2015-02-26 | 2023-08-31 | Takeda Pharmaceuticals Co | Tableta koja sadrži derivat metoksiuree i čestice manitola |
| ES2882255T3 (es) | 2015-07-01 | 2021-12-01 | California Inst Of Techn | Sistemas de administración basados en polímeros de ácido múcico catiónicos |
| AR106472A1 (es) | 2015-10-26 | 2018-01-17 | Gilead Apollo Llc | Inhibidores de acc y usos de los mismos |
| EP3380479B1 (en) | 2015-11-25 | 2022-12-07 | Gilead Apollo, LLC | Triazole acc inhibitors and uses thereof |
| KR20180082556A (ko) | 2015-11-25 | 2018-07-18 | 길리어드 아폴로, 엘엘씨 | 피라졸 acc 억제제 및 그의 용도 |
| BR112018009212B1 (pt) | 2015-11-25 | 2022-06-14 | Gilead Apollo, Llc | Método para controlar patógenos fúngicos agrícolas |
| MX2018006288A (es) | 2015-11-25 | 2018-09-07 | Gilead Apollo Llc | Inhibidores de acc tipo ester y usos de los mismos. |
| RU2610281C1 (ru) * | 2016-02-26 | 2017-02-08 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ НАУКИ ИНСТИТУТ ОРГАНИЧЕСКОЙ ХИМИИ им. Н.Д. ЗЕЛИНСКОГО РОССИЙСКОЙ АКАДЕМИИ НАУК (ИОХ РАН) | Способ получения 2-фтор-3-метилбут-2-ениламина или его гидрохлорида (Варианты) |
| MX2018010427A (es) | 2016-03-02 | 2019-03-06 | Gilead Apollo Llc | Formas solidas de un inhibidor de tienopirimidindiona acetil coa carboxilasa y metodos para su produccion. |
| FI3518932T3 (fi) | 2016-09-30 | 2025-02-03 | Sumitomo Pharma Switzerland Gmbh | Eturauhassyövän hoito |
| DK3518933T4 (da) | 2016-09-30 | 2025-04-22 | Takeda Pharmaceuticals Co | Fremgangsmåder til behandling af uterusfibromer og endometriose |
| PT3600309T (pt) | 2017-03-28 | 2022-10-03 | Gilead Sciences Inc | Combinações terapêuticas para o tratamento de doenças hepáticas |
| KR20250117836A (ko) | 2017-06-05 | 2025-08-05 | 깃세이 야쿠힌 고교 가부시키가이샤 | 자궁내막증의 치료를 위한 고나도트로핀 방출 호르몬 길항제 투약 요법 |
| US12441738B2 (en) | 2018-03-14 | 2025-10-14 | Assia Chemical Industries Ltd. | Solid state forms of Relugolix |
| EP3765464A1 (en) | 2018-03-14 | 2021-01-20 | Teva Pharmaceuticals USA, Inc. | Solid state forms of relugolix |
| CA3099440A1 (en) | 2018-06-13 | 2019-12-19 | California Institute Of Technology | Nanoparticles for crossing the blood brain barrier and methods of treatment using the same |
| CN113164466B (zh) | 2018-09-11 | 2025-07-08 | 柯瑞斯公司 | 使用具有锌结合部分的磷酸肌醇3-激酶抑制剂的联合治疗 |
| EP3873465B1 (en) | 2018-10-29 | 2025-01-15 | Kissei Pharmaceutical Co., Ltd. | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis |
| EP3876943A2 (en) | 2018-11-07 | 2021-09-15 | ObsEva S.A. | Compositions and methods for the treatment of estrogen-dependent disorders |
| EP3666776A1 (en) * | 2018-12-11 | 2020-06-17 | Sandoz AG | Hydrate of a gonadotropin-releasing hormone receptor antagonist |
| WO2020230094A1 (en) * | 2019-05-15 | 2020-11-19 | Dr. Reddy’S Laboratories Limited | Amorphous and crystalline forms of relugolix |
| CN110194776B (zh) * | 2019-06-27 | 2021-05-28 | 四川伊诺达博医药科技有限公司 | 一种瑞卢戈利的合成方法 |
| WO2021018105A1 (en) * | 2019-07-29 | 2021-02-04 | Sunshine Lake Pharma Co., Ltd. | Substituted pyrimidinedione compounds and uses thereof |
| CN114174302A (zh) * | 2019-08-02 | 2022-03-11 | 庄信万丰股份有限公司 | 瑞卢戈利的固态形式 |
| CN112321602A (zh) * | 2019-08-05 | 2021-02-05 | 苏州鹏旭医药科技有限公司 | 一种瑞卢戈利药物中间体的制备方法 |
| CN114364384A (zh) | 2019-08-08 | 2022-04-15 | 奥布赛瓦股份公司 | 用于治疗雌激素依赖性病症的GnRH拮抗剂 |
| US20220305017A1 (en) | 2019-08-08 | 2022-09-29 | ObsEva S.A. | Compositions and methods for the treatment of estrogen-dependent disorders |
| CN112390812A (zh) * | 2019-08-14 | 2021-02-23 | 苏州鹏旭医药科技有限公司 | 瑞卢戈利化合物的晶型和无定型固体及其制备方法 |
| WO2021031148A1 (zh) * | 2019-08-21 | 2021-02-25 | 深圳仁泰医药科技有限公司 | 促性腺素释放激素拮抗剂的晶型及其制备方法和用途 |
| CN115175912B (zh) * | 2019-10-10 | 2025-04-11 | 住友制药瑞士有限公司 | N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n′-甲氧基脲的结晶溶剂化形式 |
| CN115279769A (zh) * | 2019-10-10 | 2022-11-01 | 梦欧文科学有限责任公司 | N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式 |
| CN112745304A (zh) * | 2019-10-29 | 2021-05-04 | 上海度德医药科技有限公司 | 一种Relugolix的制备方法及中间体化合物 |
| CN113444105A (zh) * | 2020-03-27 | 2021-09-28 | 南京海润医药有限公司 | 一种Relugolix的制备方法 |
| CN111333633B (zh) * | 2020-04-01 | 2023-10-20 | 江西科睿药业有限公司 | 一种瑞卢戈利的中间体化合物及其制备方法和用途 |
| CN111574534B (zh) * | 2020-05-25 | 2021-06-04 | 东莞市东阳光新药研发有限公司 | 苯基取代的噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮类化合物及其用途 |
| BR112022023937A2 (pt) | 2020-05-29 | 2022-12-27 | Myovant Sciences Gmbh | Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina |
| CN111793078B (zh) * | 2020-07-03 | 2022-02-01 | 东莞市东阳光新药研发有限公司 | 双环含氮杂芳基取代的嘧啶二酮类化合物及其用途 |
| CN111875614B (zh) * | 2020-07-03 | 2022-04-29 | 东莞市东阳光新药研发有限公司 | 杂环基取代的噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮类化合物及其用途 |
| CN111909168B (zh) * | 2020-07-31 | 2022-02-01 | 广东东阳光药业有限公司 | 含氮杂环基取代的嘧啶二酮类化合物及其用途 |
| CN111925379B (zh) * | 2020-07-31 | 2022-02-15 | 广东东阳光药业有限公司 | 含氮杂芳基取代的嘧啶二酮类化合物及其用途 |
| CN113754679B (zh) * | 2020-09-09 | 2023-04-07 | 广东东阳光药业有限公司 | 取代的嘧啶二酮类化合物及其用途 |
| CN112047957B (zh) * | 2020-09-09 | 2022-02-01 | 广东东阳光药业有限公司 | 取代的嘧啶二酮类化合物及其用途 |
| CN112142757B (zh) * | 2020-09-29 | 2022-02-15 | 广东东阳光药业有限公司 | 五元含氮杂芳基取代的嘧啶二酮类化合物及其用途 |
| WO2022101303A1 (en) | 2020-11-11 | 2022-05-19 | Myovant Sciences Gmbh | Methods of administering relugolix |
| CN112552312B (zh) * | 2020-12-07 | 2022-08-05 | 杭州科巢生物科技有限公司 | 一种瑞卢戈利或其盐的合成方法 |
| CN113620972A (zh) * | 2021-02-02 | 2021-11-09 | 奥锐特药业(天津)有限公司 | 瑞卢戈利新晶型及其制备方法 |
| CN114907370B (zh) | 2021-02-10 | 2023-11-03 | 奥锐特药业(天津)有限公司 | 高纯度的噻吩并嘧啶化合物及其制备方法 |
| CN115073491A (zh) * | 2021-03-12 | 2022-09-20 | 上海医药工业研究院 | 一种瑞卢戈利中间体、其制备方法及其应用 |
| WO2022214645A1 (en) | 2021-04-09 | 2022-10-13 | Farmhispania Group, S.L. | Processes and intermediates for the preparation of relugolix |
| CN113135934A (zh) * | 2021-04-28 | 2021-07-20 | 北京海美源医药科技有限公司 | 用于制备瑞卢戈利的中间体化合物及其制备方法和瑞卢戈利的制备方法 |
| CN115260211B (zh) * | 2021-04-29 | 2024-02-06 | 长春金赛药业有限责任公司 | 含噻吩稠环类衍生物、药物组合物及其制备方法和应用 |
| JP2024540922A (ja) | 2021-10-18 | 2024-11-06 | スミトモ ファーマ スウィッツァーランド ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素のエタノール溶媒和物の結晶形 |
| EP4428137A1 (en) * | 2021-11-01 | 2024-09-11 | Shandong Luye Pharmaceutical Co., Ltd. | Gonadotropin-releasing hormone antagonist, and preparation method therefor and use thereof |
| CN114230576A (zh) * | 2021-12-21 | 2022-03-25 | 伊诺药物研究(南京)有限公司 | 一种瑞卢戈利的制备方法 |
| CN117285506A (zh) * | 2022-07-14 | 2023-12-26 | 江西同和药业股份有限公司 | 一种瑞卢戈利中间体及其制备方法 |
| CN115417883B (zh) * | 2022-09-16 | 2024-08-27 | 浙江科聚生物医药有限公司 | 一种瑞卢戈利的晶型及其制备方法 |
| WO2024126674A1 (en) | 2022-12-15 | 2024-06-20 | Medichem, S.A. | Process for the preparation of relugolix |
| WO2024222827A1 (zh) * | 2023-04-27 | 2024-10-31 | 山东绿叶制药有限公司 | 一种噻吩并嘧啶类化合物的盐型、晶型及其制备方法和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6048863A (en) * | 1994-04-19 | 2000-04-11 | Takeda Chemical Industries, Ltd. | Condensed-ring thiophene derivatives and thienopyrimidine derivatives, their production and use |
| UY23948A1 (es) | 1995-02-08 | 2001-10-25 | Takeda Chemical Industries Ltd | Derivados de anillos condensados de tiofeno su producción y uso. |
| US6297379B1 (en) * | 1999-03-24 | 2001-10-02 | Takeda Chemical Industries, Ltd. | Thienopyrimidine compounds, their production and use |
| TWI225863B (en) * | 1999-03-24 | 2005-01-01 | Takeda Chemical Industries Ltd | Thienopyrimidine compounds, their production and use |
| JP2001316391A (ja) * | 2000-02-29 | 2001-11-13 | Takeda Chem Ind Ltd | チエノピリミジン誘導体の製造法 |
| CN1539836A (zh) * | 2000-02-29 | 2004-10-27 | 武田药品工业株式会社 | 制备噻吩并嘧啶衍生物的方法 |
| JP2001354588A (ja) * | 2000-04-13 | 2001-12-25 | Takeda Chem Ind Ltd | アルツハイマー病予防・治療剤 |
| WO2001078780A1 (en) * | 2000-04-13 | 2001-10-25 | Takeda Chemical Industries, Ltd. | Preventives/remedies for alzheimer's disease |
| CA2407472A1 (en) * | 2000-06-14 | 2002-10-23 | Takeda Chemical Industries, Ltd. | Sustained release compositions |
| JP2002068982A (ja) * | 2000-06-14 | 2002-03-08 | Takeda Chem Ind Ltd | 徐放性組成物 |
| JP2002080397A (ja) * | 2000-07-05 | 2002-03-19 | Takeda Chem Ind Ltd | 性ホルモン依存性疾患の治療用医薬製剤 |
| WO2002002144A1 (fr) | 2000-07-05 | 2002-01-10 | Takeda Chemical Industries, Ltd. | Preparations medicinales pour le traitement des maladies dependant des hormones sexuelles |
| WO2002024230A1 (en) * | 2000-09-22 | 2002-03-28 | Takeda Chemical Industries, Ltd. | Solid preparations |
| JP2002167327A (ja) * | 2000-09-22 | 2002-06-11 | Takeda Chem Ind Ltd | 固形製剤 |
| AU2002218494A1 (en) * | 2000-11-29 | 2002-06-11 | Takeda Chemical Industries Ltd. | Medicinal compositions and process for producing the same |
| AU2002221139A1 (en) * | 2000-12-15 | 2002-06-24 | Takeda Chemical Industries Ltd. | Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof |
| EP1370562A1 (en) * | 2001-02-14 | 2003-12-17 | Warner-Lambert Company LLC | Thieno[2,3-d]pyrimidindione derivatives as matrix metalloproteinase inhibitors |
| JP5072166B2 (ja) * | 2002-01-30 | 2012-11-14 | 武田薬品工業株式会社 | チエノピリミジン化合物、その製造法および用途 |
| EP1479684A4 (en) | 2002-01-30 | 2006-01-04 | Takeda Pharmaceutical | THIENOPYRIMIDINES, METHODS OF MAKING AND USING SAME |
| JP2004002321A (ja) * | 2002-03-11 | 2004-01-08 | Takeda Chem Ind Ltd | 性ホルモン依存性疾患治療剤 |
| US20050159361A1 (en) | 2002-03-11 | 2005-07-21 | Takahito Hara | Remedies for sex hormone-dependent disease |
| JP2004002377A (ja) * | 2002-04-12 | 2004-01-08 | Takeda Chem Ind Ltd | ホットフラッシュ予防・治療剤 |
| EP1495768A4 (en) | 2002-04-12 | 2007-12-05 | Takeda Pharmaceutical | MEANS FOR THE PREVENTION / TREATMENT OF HITZEWALLUNGEN |
-
2004
- 2004-01-28 EP EP04705950A patent/EP1591446B1/en not_active Expired - Lifetime
- 2004-01-28 WO PCT/JP2004/000741 patent/WO2004067535A1/ja not_active Ceased
- 2004-01-28 ES ES04705950T patent/ES2410814T3/es not_active Expired - Lifetime
- 2004-01-28 PL PL378002A patent/PL214756B1/pl unknown
- 2004-01-28 DK DK04705950.6T patent/DK1591446T3/da active
- 2004-01-28 MX MXPA05007990A patent/MXPA05007990A/es active IP Right Grant
- 2004-01-28 CN CNB2004800087989A patent/CN100360538C/zh not_active Expired - Lifetime
- 2004-01-28 CA CA2514407A patent/CA2514407C/en not_active Expired - Fee Related
- 2004-01-28 RU RU2005127052/04A patent/RU2331648C2/ru active
- 2004-01-28 SI SI200432035T patent/SI1591446T1/sl unknown
- 2004-01-28 AU AU2004207706A patent/AU2004207706B2/en active Active
- 2004-01-28 NZ NZ541772A patent/NZ541772A/en not_active IP Right Cessation
- 2004-01-28 BR BRPI0407082A patent/BRPI0407082C1/pt not_active IP Right Cessation
- 2004-01-28 KR KR1020057014100A patent/KR101074462B1/ko not_active Expired - Lifetime
- 2004-01-28 US US10/544,069 patent/US7300935B2/en active Active
- 2004-01-28 PT PT47059506T patent/PT1591446E/pt unknown
- 2004-01-28 CN CNA2007101869688A patent/CN101153042A/zh active Pending
- 2004-01-28 ZA ZA200506611A patent/ZA200506611B/en unknown
-
2005
- 2005-07-25 IL IL169869A patent/IL169869A/en active IP Right Grant
- 2005-08-25 NO NO20053974A patent/NO331981B1/no not_active IP Right Cessation
- 2005-08-25 CO CO05084855A patent/CO5590921A2/es unknown
-
2007
- 2007-08-31 US US11/848,939 patent/US8058280B2/en active Active
-
2011
- 2011-09-23 US US13/242,541 patent/US8735401B2/en not_active Expired - Lifetime
-
2013
- 2013-05-29 CY CY20131100419T patent/CY1114008T1/el unknown
-
2014
- 2014-04-11 US US14/251,119 patent/US9346822B2/en not_active Expired - Lifetime
-
2021
- 2021-11-19 HU HUS2100052C patent/HUS2100052I1/hu unknown
- 2021-11-19 FR FR21C1056C patent/FR21C1056I2/fr active Active
- 2021-11-24 LT LTPA2021529C patent/LTC1591446I2/lt unknown
- 2021-12-16 NO NO2021052C patent/NO2021052I1/no unknown
- 2021-12-22 CY CY2021039C patent/CY2021039I1/el unknown
- 2021-12-31 NL NL301158C patent/NL301158I2/nl unknown
-
2022
- 2022-01-03 BE BE2022C501C patent/BE2022C501I2/fr unknown